Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
- Conditions
- Prostate Cancer MetastaticCastration-resistant Prostate Cancer
- Interventions
- Other: Exercise
- Registration Number
- NCT03658486
- Lead Sponsor
- Queen's University, Belfast
- Brief Summary
This feasibility study will investigate whether men with metastatic prostate cancer can take part in and progress through a home-based exercise program. This study will evaluate the effects of exercise on a range of disease and treatment-related outcomes.
- Detailed Description
This 12 week multicomponent, tailored, progressive program will consist of both moderate intensity walking and strengthening exercises at home. This single centre, single arm study will incorporate a behavioural change consultation at baseline and weekly behavioural support throughout. This study will follow-up patients at 24 weeks to determine exercise maintenance. Outcome measures will be completed at baseline, 12 and 24 weeks. A qualitative evaluation will be conducted after the 24 week follow-up to determine impact, patient experience and measures that might assist in refining the program.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 30
- Histologically documented adenocarcinoma of the prostate with progressive systemic metastatic disease despite castrate levels of testosterone (<50ng/dL).
- At enrolment, patients must have demonstrated progressive disease since the most recent change in therapy.
- Patients must be on ADT with a GnRH agonist/antagonist or prior bilateral orchiectomy. All patients must be on ADT during the study period.
- ≥ 4 weeks since last surgery and fully recovered.
- No known contraindications to moderate intensity exercise such as (but not limited to) brain metastases, acute congestive heart failure, unstable angina, serious or non-healing wound, peripheral neuropathy greater than or equal to Grade 3. Recent myocardial infarction.
- Age ≥ 18 years.
- ECOG performance status 0-2.
- Medical clearance by treating clinician.
- Men currently exceeding ACSM recommended exercise guidelines (150 mins of moderate and/or 60 mins of high intensity exercise per week).
- Men with brain metastases.
- Men with a currently active second malignancy other than non-melanoma skin cancer.
- Congestive heart failure or recent serious cardiovascular event.
- Chest pain brought on by physical activity.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Exercise Exercise 12 weeks of progressive, home-based, moderate intensity, aerobic and strengthening exercise. Aerobic exercise will be completed 5 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous brisk walking at week 12. Strengthening exercises will involve whole body activities and commence with 1 set of each exercise (8-15 repetitions) and progress to 3 sets. The strengthening exercises will gradually progress in difficulty throughout the program.
- Primary Outcome Measures
Name Time Method Feasibility - attrition rates. Throughout the 24 week study period. The number of patients that withdraw.
Feasibility - adherence to the exercise intervention. Throughout the 24 week study period. Determine the percentage of patients adhering to the program and the weekly behavioral consultation sessions.
Feasibility - patient experience. Following the study conclusion at 24 weeks. Determined by qualitative evaluation, using semi-structured interviews, to assess experiences, accessibility and acceptability of the exercise intervention.
Feasibility - recruitment. At baseline. The number of participants that agree to participate or are excluded.
Feasibility - safety / adverse events. Monitored throughout the 24 week study period. Any safety / adverse events, in general or in relation to the exercise program, will be documented by the research team.
- Secondary Outcome Measures
Name Time Method Hip and waist circumference analysis. At baseline, 12 and 24 weeks. Hip and waist circumference will be measured in cms.
Cancer-related fatigue by questionnaire. At baseline, 12 and 24 weeks. Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.
Physical fitness assessment. At baseline, 12 and 24 weeks. Distance covered in meters during a six minute walk test will be recorded.
Anthropometric assessment. At baseline, 12 and 24 weeks. Height will be measured in cm and body weight in kg, which will be combined to report BMI in kg/m(squared).
Perceived physical activity levels. At baseline, 12 and 24 weeks. Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline.
Quality of life will be measured using questionnaires. At baseline, 12 and 24 weeks. Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).
Pain will be measured through a questionnaire. At baseline, 12 and 24 weeks. Bone pain will be monitored using the Brief Pain Inventory Short Form (BPI-SF).
Objectively measure of physical activity levels. At baseline, 12 and 24 weeks. Patients will wear an accelerometer for 7 full days.
Quality of life will be measured using a questionnaire. At baseline, 12 and 24 weeks. Quality of life will be measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire. Patients will score a series of questions (0 = not at all; 4 = very much) in five sections (physical well-being; social/family well-being; emotional well-being; functional well-being; additional concerns) for the past 7 days. Higher scores will suggest better quality of life.
Functional ability assessment. At baseline, 12 and 24 weeks. The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.
Trial Locations
- Locations (1)
Northern Ireland Cancer Centre, Belfast City Hospital
🇬🇧Belfast, United Kingdom